Arix Bioscience Plc Giles Kerr Appointed to Board of Directors (7484T)
October 17 2017 - 2:00AM
UK Regulatory
TIDMARIX
RNS Number : 7484T
Arix Bioscience Plc
17 October 2017
Arix Bioscience appoints Giles Kerr to Board of Directors
LONDON, 17 October 2017: Arix Bioscience plc (LSE: ARIX) ("Arix
Bioscience" or "the Company"), a global healthcare and life science
company supporting medical innovation, today announces the
appointment of Giles Kerr as a Non-Executive Director of the
Company and chairman of the Board's Audit Committee. The
appointment is with immediate effect.
Giles Kerr has 36 years' experience in finance across a broad
range of industrial sectors with a particular focus on life
sciences. He is currently the Director of Finance at the University
of Oxford, and during his tenure he has established a successful
investment office with GBP2.5bn under management and a GBP650m
early-stage investment fund. He is also a Director of Oxford
University Innovation Ltd, Adaptimmune Therapeutics plc, BTG plc,
Senior plc and PayPoint plc.
He was previously the Chief Financial Officer of Amersham plc,
acquired by GE Healthcare in 2004, and prior to that he was a
partner with Arthur Andersen in the UK. He is a Fellow of Keble
College, Oxford, a graduate of the University of York and a Fellow
of the Institute of Chartered Accountants in England and Wales.
Jonathan Peacock, Chairman of Arix Bioscience, said: "Giles
brings a strong combination of life sciences and financial
experience, as well as valuable insight into the funding and
commercialisation of world-class academic research. I am very
pleased to announce his appointment, and we look forward to working
with him."
Giles Kerr said: "I am delighted to join the Board of Arix
Bioscience, with its world-class team and a fast-developing
portfolio of innovative young businesses. I look forward to working
with the Board and executive team to develop important new
therapies for patients and realise substantial value for
shareholders."
For more information, please contact:
Arix Bioscience plc
Matthew Cole, Communications Director
+44 (0) 20 7290 1065
Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700
arix@consilium-comms.com
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science
company supporting medical innovation. Headquartered in London and
with an office in New York, Arix Bioscience sources, finances and
builds world class healthcare and life science businesses
addressing medical innovation at all stages of development.
Operations are supported by privileged access to breakthrough
academic science and strategic relationships with leading research
accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market of the London
Stock Exchange. For further information, please visit
www.arixbioscience.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAUNVBRBUARAAA
(END) Dow Jones Newswires
October 17, 2017 02:00 ET (06:00 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Apr 2023 to Apr 2024